

Imaging Inflammation: The Hidden Driver of Disease

Daniel Okoro *

Department of Surgical Pathology, Lagos Medical University, Lagos, Nigeria

Introduction

Inflammation is a fundamental biological response, but when it becomes chronic, it sets the stage for a wide range of diseases by creating persistent lesions and tissue damage. Let's break down the connection to cancer. In the gut, chronic inflammation is not just random damage; specific molecular pathways like NF- κ B and STAT3 are activated, directly fueling the growth of colorectal tumors. This research clearly connects inflammatory bowel disease to a higher cancer risk, underscoring the need to manage inflammation to prevent malignancy[1].

Similarly, inflammatory breast cancer can be tricky because it often mimics a simple infection. A new ultrasound technique called superb microvascular imaging, or SMI, provides a highly detailed look at blood flow, revealing that malignant inflammatory lesions have distinct and chaotic vessel patterns compared to benign ones, offering a powerful tool for earlier diagnosis[9].

The diagnostic challenges extend to other areas. In the brain, distinguishing between a tumor and an inflammatory lesion, like those found in multiple sclerosis, can be incredibly difficult with a standard MRI. What this really means is that doctors are turning to advanced MRI techniques like perfusion imaging and spectroscopy. By looking at blood flow and chemical composition, they can get crucial clues to make a non-invasive diagnosis and potentially avoid risky biopsies[3].

This same imaging modality is a game-changer for the spinal cord. Different MRI sequences can reveal the precise size, shape, and location of inflammatory lesions, creating a detailed map that helps differentiate between diseases like multiple sclerosis and neuromyelitis optica and track disease activity over time[7].

Moving to the skin, diagnosing inflammatory lesions is not just about looking at a rash. A much clearer picture emerges by combining clinical observation with histopathology and molecular analysis. This integrated approach is the key to distinguishing between conditions that look similar, such as psoriasis and eczema, and tailoring the correct treatment[2].

Here's the thing about painful sores in the mouth. A protein complex called the NLRP3 inflammasome acts like a cellular alarm system. Research shows how this system can go into overdrive, contributing to lesions found in conditions like lichen planus. Understanding this mechanism opens the door to targeted therapies that could quiet this specific inflammatory pathway[4].

Within our circulatory system, inflammation can be visualized using PET/CT scans. For conditions like vasculitis, a radioactive sugar tracer can pinpoint areas of high metabolic activity, signaling inflammation in and around blood vessels. This is crucial not only for diagnosis but also for monitoring treatment effectiveness and spotting a relapse before it becomes obvious[5].

This perspective has completely changed our view of atherosclerosis. For a long time, we thought of it as simple cholesterol buildup, but it is fundamentally an inflammatory disease. The arterial plaque is an active inflammatory site teeming with immune cells, and it is this inflammation that makes plaques unstable and prone to rupture, which is the actual cause of most heart attacks and strokes[10].

In major organs, the story is similar. For chronic lung diseases like COPD, the goal is to move beyond simple lung function tests by using serum biomarkers. These substances in the blood can reflect underlying inflammation, paving the way for a more personalized approach to predict disease flares and guide therapy[6].

This direct link is also crystal clear in the liver, where chronic inflammation leads to fibrosis, the scarring that causes cirrhosis. When liver cells are damaged, they release signals that create a sustained inflammatory response, activating other cells to produce excessive scar tissue. The takeaway is that controlling inflammation is essential to halting the progression of liver disease[8].

Description

Chronic inflammation is now understood not merely as a symptom but as a primary driver of some of the most challenging diseases. It actively promotes malignancy through specific molecular pathways. For instance, in the gut, the inflammatory response activates signals like NF- κ B and STAT3 that directly encourage tumor growth, explaining the well-established link between inflammatory bowel disease and colorectal cancer [1]. This concept of inflammation-driven disease extends to the cardiovascular system, where atherosclerosis is no longer seen as a passive buildup of cholesterol. Instead, arterial plaques are recognized as active inflammatory lesions, filled with immune cells. This underlying inflammation is what makes a plaque unstable and likely to rupture, triggering a heart attack or stroke [10]. A similar process occurs in the liver, where persistent cell damage leads to a chronic inflammatory state. This response recruits immune cells that, in turn, signal other cells to produce excessive scar tissue, a process known as fibrosis, which ultimately progresses to cirrhosis. In all these cases, managing the inflammation is key to preventing or halting disease progression [8].

The presence of inflammatory lesions also creates significant diagnostic hurdles, as they can closely mimic other conditions, particularly cancer. In neurology, differentiating a brain tumor from an inflammatory lesion, such as one caused by multiple sclerosis, is a major challenge with standard imaging [3]. This ambiguity can lead to diagnostic delays or the need for invasive procedures like biopsies. A similar issue arises with inflammatory breast cancer, which can present with redness and swelling, easily mistaken for a common infection like mastitis, delaying a critical cancer diagnosis [9]. Even in dermatology, visually similar rashes from conditions like psoriasis and eczema require more than a simple clinical look; they

necessitate a deeper analysis to ensure the correct diagnosis and treatment are provided [2]. These examples highlight a critical need for advanced diagnostic tools that can look beyond surface-level symptoms to reveal the true nature of a lesion.

To address these diagnostic challenges, medicine has turned to advanced imaging and integrated analytical approaches. In the brain, advanced MRI techniques like perfusion imaging, which measures blood flow, and spectroscopy, which assesses chemical composition, provide crucial data to distinguish between tumoral and non-tumoral lesions without a biopsy [3]. For the spinal cord, specific MRI sequences create a detailed map of lesions, helping to differentiate complex neurological conditions [7]. In breast imaging, superb microvascular imaging (SMI) offers a new frontier for ultrasound by visualizing blood flow patterns with such high detail that it can distinguish the chaotic vasculature of a malignant lesion from a benign one [9]. For systemic inflammation in blood vessels, PET/CT scans combined with a radioactive tracer can light up areas of high metabolic activity, pinpointing vasculitis and allowing doctors to monitor treatment response effectively [5]. This shift towards more sophisticated imaging provides the clarity needed for accurate and timely diagnosis.

Beyond imaging, the focus is increasingly on the molecular underpinnings of inflammation to develop more targeted therapies. Understanding that a specific cellular alarm system, the NLRP3 inflammasome, can go into overdrive to cause oral inflammatory lesions allows for the development of drugs that can selectively quiet this pathway [4]. In chronic lung diseases like COPD and pulmonary fibrosis, the field is moving toward identifying serum biomarkers. These blood-based indicators of inflammation could offer a personalized way to predict disease flares and tailor treatments, moving beyond one-size-fits-all approaches [6]. This molecular-level understanding is also key in dermatology, where combining clinical observation with histopathology and molecular analysis ensures that conditions like psoriasis and eczema receive the most effective, tailored therapies [2]. Ultimately, this granular approach promises a future of precision medicine where treatments are aimed at the specific biological mechanisms driving the disease.

Conclusion

The provided research highlights that chronic inflammation is a critical driver of numerous diseases, not just a side effect. It establishes a direct link between sustained inflammation and the development of severe conditions like colorectal cancer, liver fibrosis, and atherosclerosis by showing how specific molecular pathways get activated to fuel disease progression. A major theme is the diagnostic challenge these inflammatory lesions present, as they often mimic other pathologies, such as brain tumors or breast cancer. To overcome this, advanced imaging techniques are proving essential. Methods like specialized MRI sequences, PET/CT scans, and superb microvascular imaging (SMI) offer non-invasive ways to differentiate between benign and malignant lesions by analyzing blood flow, chemical composition, and metabolic activity. This allows for more accurate diagnoses and can help avoid risky procedures like biopsies. Furthermore, the research emphasizes a shift towards a molecular-level understanding. By identifying key mechanisms like the NLRP3 inflammasome in oral lesions or searching for serum biomarkers in lung disease, scientists are paving the way for targeted therapies. This integrated approach, combining clinical observation with advanced imaging and molecular analysis, is key to diagnosing conditions ranging from skin rashes to spinal cord lesions, ultimately enabling more personalized and effective

treatments.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Yuxin Wang, Jiaxin Liu, Yuhan Zhang, Jingyu Wang, Chunyan Wang. "The Role of Inflammatory Lesions in the Progression of Colorectal Cancer: From Molecular Mechanisms to Clinical Perspectives." *Int J Mol Sci* 24 (2023):7087.
2. Maria R. Richetta, Angelo V. Marzano, Luca Fania, Annamaria G. Solimani, Luca E. Tassone, Claudio Feliciani. "Inflammatory Lesions of the Skin: A Clinical, Histopathological, and Molecular Update." *J Clin Med* 11 (2022):5937.
3. Francesco D'Amore, Luigi Cirillo, Andrea D'Amico, Sirio Cocozza, Massimo Galbiati, Arturo Brunetti. "Advanced MRI Techniques for Differentiating Tumoral and Non-Tumoral Inflammatory Brain Lesions." *Cancers (Basel)* 14 (2022):835.
4. Adriana L. P. da Silva, Bruna L. F. P. da Silva, Débora C. C. de Alencar, Roseana de L. A. Freitas, Lélia M. G. de L. B. da Silva. "Role of NLRP3 Inflammasome in the Pathogenesis of Oral Inflammatory Lesions." *Mediators Inflamm* 2021 (2021):6692296.
5. Giorgio Treglia, Cyril D. J. Doderer, Fabienne M. A. P. Leiner, Andor W. J. M. Glaudemans, Riemer H. J. A. Slart. "FDG-PET/CT(A) for Imaging of Vascular and Perivascular Inflammatory Lesions." *Curr Pharm Des* 26 (2020):2475-2483.
6. Andrea P. E. G. Posso, Marjolein Y. B. G. Poels, Kristof G. J. van der Heijden, Martijn A. Spruit, Frits M. E. Franssen. "Serum Biomarkers in Chronic Inflammatory Lung Diseases: A Narrative Review." *Int J Mol Sci* 24 (2023):2197.
7. Maura Majori, Domenico De Fino, Giancarlo L. Russo, Letterio S. Politi, Andrea Falini. "Spinal cord inflammatory lesions: the role of magnetic resonance imaging." *Radial Med* 126 (2021):843-853.
8. Patricia Sancho, Elena Fernández-Iglesias, Ana Gracia-Sancho, Anna Moles, Alba Rodríguez-Garriz, Juan José Marín. "Inflammation, a key process in liver fibrogenesis." *World J Gastroenterol* 27 (2021):7401-7427.
9. Yuancheng Wang, Chunping Jiang, Xiangning He, Xueying Li, Wei Luo. "Role of superb microvascular imaging in distinguishing between inflammatory and non-inflammatory breast lesions." *J Int Med Res* 48 (2020):300060519888841.
10. Nihar R. Desai, Divya P. Gholkar, Sandhya L. Sitasawad, Yogesh M. Kulkarni. "Atherosclerosis Is an Inflammatory Disease: A Perspective." *ACS Omega* 9 (2024):9789-9801.

How to cite this article: , Daniel Okoro. "Imaging Inflammation: The Hidden Driver of Disease." *J Surg Path Diag* 07 (2025):20.

***Address for Correspondence:** Daniel, Okoro , Department of Surgical Pathology, Lagos Medical University, Lagos, Nigeria, E-mail: d.okoro@lagosmed.ng

Copyright: © 2025 O. Daniel This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Received: 01-May-2025, Manuscript No. j spd-25-172595; **Editor assigned:** 05-May-2025, PreQC No. P-172595; **Reviewed:** 19-May-2025, QC No. Q-172595; **Revised:** 22-May-2025, Manuscript No. R-172595; **Published:** 29-May-2025, DOI: 10.37421/2684-4575.2025.7.020
